Pebblebrook's Q4 Beat Looks Strong. The 2026 CapEx Bill Tells a Different Story.
Pebblebrook posted 3.9% same-property EBITDA growth in Q4 and guided 2-4% RevPAR growth for 2026. But $65-75 million in capital improvements means owners should be asking what that spend does to free cash flow before celebrating the top line.
Same-property hotel EBITDA of $64.6 million in Q4 2025, beating their own midpoint by $2.2 million. Full-year adjusted EBITDA up 11.1% to $69.7 million. San Francisco portfolio delivering a 58.5% full-year EBITDA increase. Those are the numbers Pebblebrook wants you to see when they host analysts in New York.
Here's the number they'll spend less time on: $65 million to $75 million in capital improvements for 2026. That's the reinvestment required to sustain the RevPAR trajectory they're guiding (2% to 4%). Run the math on a portfolio of roughly 50 properties and you're looking at $1.3 million to $1.5 million per asset in capital spend this year alone. That's not maintenance. That's the cost of keeping the growth story intact. The $450 million unsecured term loan they closed in February and the $650 million revolver extension aren't just balance sheet optimization... they're funding the renovation pipeline that makes the 2026 guidance achievable. Debt is cheap until the RevPAR growth it's supposed to fund doesn't materialize.
The San Francisco story deserves scrutiny. A 32% Q4 total RevPAR increase and 58.5% full-year EBITDA growth sounds extraordinary. It is extraordinary. It's also a recovery story, not a growth story. San Francisco's hotel market was among the most depressed post-pandemic markets in the country. Recovering from a historically low base produces impressive percentages. The question for 2026 is whether San Francisco sustains momentum or mean-reverts once the easy comps are gone. Pebblebrook's broader portfolio guidance of 2-4% RevPAR growth suggests management isn't banking on another 32% quarter from any single market.
Group and transient pace running $21 million ahead, or 2.4% over prior year final room revenues, provides some visibility. But pace is a snapshot, not a guarantee. I've analyzed enough REIT portfolios to know that pace in April tells you what's booked. It doesn't tell you what cancels, what compresses, or what happens if the macro environment shifts between now and Q4. The 2026 guidance range itself (2% to 4%) is wide enough to accommodate meaningful variance... the difference between the low and high end on a portfolio this size is roughly $15-20 million in room revenue.
Pebblebrook reports Q1 results on April 28. That's the first real data point on whether the 2026 thesis holds. Watch two things: flow-through on the RevPAR growth (revenue increasing faster than costs, or the opposite?) and renovation disruption disclosure. $65-75 million in capital improvements means rooms out of inventory, which means RevPAR per available room looks different than RevPAR per renovated room. The distinction matters more than most analyst presentations acknowledge.
Here's what I want you thinking about if you're an asset manager or owner watching Pebblebrook's investor conference. The headline numbers look clean. But run the CapEx against the EBITDA growth yourself... $65-75 million in improvements against $69.7 million in adjusted EBITDA means they're reinvesting nearly dollar-for-dollar. That's a growth play, not a dividend play. If you're benchmarking your own portfolio against Pebblebrook's RevPAR guidance, strip out the San Francisco recovery effect first... that market is operating off a base that most portfolios don't share. And if you're negotiating a management agreement right now, look at how the renovation disruption is handled in the fee calculation. Rooms out of inventory during a $1.5M-per-property renovation cycle change the denominator on every performance metric. Make sure your agreement accounts for that. Don't let someone else's recovery story set unrealistic expectations for your assets.